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RESEARCH ARTICLE Open Access
Determinant roles of dendritic cell-
expressed Notch Delta-like and Jagged
ligands on anti-tumor T cell immunity
Elena E. Tchekneva1, Mounika U.L. Goruganthu1†, Roman V. Uzhachenko2†, Portia L. Thomas2,3,4†,
Anneliese Antonucci1, Irina Chekneva5, Michael Koenig1, Longzhu Piao1, Anwari Akhter1,
Maria Teresa P. de Aquino2, Parvathi Ranganathan6, Nicholas Long7, Thomas Magliery7, Anna Valujskikh8,
Jason V. Evans9, Rajeswara R. Arasada1, Pierre P. Massion10, David P. Carbone1, Anil Shanker2,4,11,12*† and
Mikhail M. Dikov1*†
Abstract
Background: Notch intercellular communication instructs tissue-specific T-cell development and function. In this
study, we explored the roles of dendritic cell (DC)-expressed Notch ligands in the regulation of T-cell effector function.
Methods: We generated mice with CD11c lineage-specific deletion of Notch Delta-like ligand (Dll)1 and Jagged (Jag)2.
Using these genetically-ablated mice and engineered pharmacological Notch ligand constructs, the roles of various
Delta-like and Jagged ligands in the regulation of T-cell-mediated immunity were investigated. We assessed tumor
growth, mouse survival, cytokine production, immunophenotyping of myeloid and lymphoid populations infiltrating
the tumors, expression of checkpoint molecules and T-cell function in the experimental settings of murine lung and
pancreatic tumors and cardiac allograft rejection. Correlative studies were also performed for the expression of NOTCH
ligands, NOTCH receptors and PD-1 on various subsets of myeloid and lymphoid cells in tumor-infiltrating immune
cells analyzed from primary human lung cancers.
Results: Mice with CD11c lineage-specific deletion of Notch ligand gene Dll1, but not Jag2, exhibited accelerated
growth of lung and pancreatic tumors concomitant with decreased antigen-specific CD8+T-cell functions and
effector-memory (Tem) differentiation. Increased IL-4 but decreased IFN-γ production and elevated populations of
T-regulatory and myeloid-derived suppressor cells were observed in Dll1-ablated mice. Multivalent clustered
DLL1-triggered Notch signaling overcame DC Dll1 deficiency and improved anti-tumor T-cell responses, whereas
the pharmacological interference by monomeric soluble DLL1 construct suppressed the rejection of mouse
tumors and cardiac allograft. Moreover, monomeric soluble JAG1 treatment reduced T-regulatory cells and
improved anti-tumor immune responses by decreasing the expression of PD-1 on CD8+Tem cells. A significant
correlation was observed between DC-expressed Jagged and Delta-like ligands with Tem-expressed PD-1 and
Notch receptors, respectively, in human lung tumor-infiltrates.
(Continued on next page)
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(Continued from previous page)
Conclusion: Our data show the importance of specific expression of Notch ligands on DCs in the regulation of T-
cell effector function. Thus, strategies incorporating selectively engineered Notch ligands could provide a novel
approach of therapeutics for modulating immunity in various immunosuppressive conditions including cancer.
Keywords: Delta-like notch ligands, Jagged, Notch receptors, Lung carcinoma, Tumor infiltrating immune cells,
Heart allograft rejection, Dendritic cells, CD8 T-cells, Regulatory T-cells, Cancer immunotherapy
Background
Signals delivered to naïve T-cells by antigen-presenting
cells (APCs) along with a specific cytokine milieu play
key roles in regulation of CD4+ and CD8+ T-cell differ-
entiation. Accumulating evidence suggests that engage-
ment of Notch ligands presented by APCs with Notch
receptors on T-cells are important regulators of T-cell
differentiation [1]. The mammalian Notch family pre-
sents an intricate intercellular communication system
that includes four known transmembrane receptors,
Notch1–4, and five cell membrane-bound Notch li-
gands, Delta-like (DLL)1, DLL3, DLL4, Jagged (Jag)1
and Jag2. Notch regulates a variety of processes in cel-
lular development and differentiation in a dose and
context-dependent manner [2]. Notch target genes be-
long to various functional classes that act as transcrip-
tional repressors to downregulate expression of
tissue-specific transcriptional activators, or regulators
of cell cycle and apoptosis [3, 4].
In the immune system, Notch provides instructive
signals for priming CD4+T-cells and governing the dif-
ferentiation of T helper (Th), follicular Th, and regula-
tory T (Treg) cells [5–11]. Notch has been shown to
promote Th1 differentiation by upregulating T-bet and
Ifn-γ expression [12]. It can also transactivate
Th2-promoting genes Il4 and Gata3 [6]. Notch
ligand-specific signaling can alter Th1 or Th2 differenti-
ation with different ligands supporting distinct
polarization of Th cells [13–16]. Most gain-of-function
studies indicate that Delta-like ligands promote
CD4+T-cell commitment to Th1 type [17, 18]. Although
controversy exists, studies support that Jagged ligands in-
duce Th2-promoting Notch signaling [17, 19]. Notch also
regulates Il17 and RORγt gene promoters to influence
Th17 differentiation [8]. In addition to guiding Th1, Th2
and Th17 differentiation, expression of Jagged ligands by
APCs or hematopoietic progenitors can favor generation
of suppressive T-cells in vitro or Treg cells in vivo [20–
22]. Systemic blockade of Jag1 and 2 with Jagged
ligand-specific antibodies overcame tumor-induced T-cell
tolerance, indicating the involvement of these ligands in
T-cell suppression [23]. Expression of Delta-like ligands,
but not Jagged, in hematopoietic compartments was al-
tered by tumor-derived factors to cause tumor-induced
immunosuppression [20, 24, 25]. An alternative hypoth-
esis posits that interaction of DLL4 expressed by dendritic
cells (DCs) and Notch1 on T-cells may fine-tune sensitiv-
ity, magnitude and quality of the CD4+T-cell response by
promoting metabolic reprogramming, rather than by spe-
cifying lineage choice following the initial exposure to the
antigen [21]. It is known that a transient pulse with high
levels of Delta-like ligands can induce Hes1 expression for
a duration that is sufficient to induce a binary cell fate
switch in T-cell or natural killer cell differentiation [22].
Both Notch1 and Notch2 have been identified as key
players in anti-tumor T-cell immunity including induction
of tumor-specific cytotoxic T lymphocytes (CTL) and
memory T-cells [21, 23, 26]. Studies also indicate that
Notch regulates effector cytokine production by
CD8+T-cells [5, 27, 28].
It is, however, unclear what specific roles different
Notch ligands play in modulating T-cell responses. In
this study, we used genetic and pharmacological ap-
proaches to investigate the roles of various Delta-like
and Jagged ligands in the regulation of
T-cell-mediated immunity in mouse models of lung
and pancreatic tumors and cardiac allograft rejection.
We found that DC-expressed DLL1, but not Jag2, is
indispensable for the induction of antigen-specific re-
sponses and generation of effector and memory
T-cells. In human lung tumor infiltrates, we noted a
significant correlation between Jag1 or Jag2-expressing
DCs with the PD-1-expressing CD8+T effector-mem-
ory (Tem) cells. In contrast, expression of DLL1 or
DLL4 in DC was positively correlated with the expres-
sion of Notch receptors on tumor-infiltrating Tem
cells. In mice lacking DLL1 in CD11c+ cells, a
Notch-activating clustered DLL1 construct could
compensate for the genetic deficiency of DLL1 on
DCs. Moreover, treatment with soluble JAG1 resulted
in the decreased differentiation of Treg cells, a de-
creased expression of PD-1 molecules on CD8+Tem
cells and improved anti-tumor responses. These data
emphasize the importance of specific expression of
Notch ligands on DCs by revealing their distinct roles
in the regulation of T-cell immunity, and suggest op-
portunities for modulating immune outcomes using
engineered Notch ligand constructs.
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Results
Deletion of Dll1 but not Jag2 in dendritic cells accelerates
tumor growth and decreases host survival
To evaluate the roles of Notch ligands DLL1 and Jag2 ex-
pression on DCs in the regulation of T-cell-mediated
anti-tumor immunity, we generated mice with
CD11c-lineage-specific deletion of their genes. Mice with
hetero- or homozygous allele deletion of Dll1 or Jag2 ap-
peared normal in gross morphology with respect to their
wild type littermates with floxed alleles, DLL1flox/flox or
Jag2flox/flox. A representative mRNA analysis of the re-
spective Notch ligands in flow-sorted CD11+ DC popula-
tions from wild type and genetically modified mice is
shown (Fig. 1a). Transcripts for the tested Notch ligand
mRNAs were absent in CD11c+ cells but present in
CD11c− splenic cells or whole splenocyte populations
from mice with homozygous deletion of the ligands.
Genetically modified mice were inoculated subcutane-
ously with lung LLC or pancreatic MT5 tumor cells.
Mice with hetero- or homozygous deletion of Dll1 allele
in CD11c+ cells exhibited remarkably accelerated LLC
tumor growth and significantly decreased survival com-
pared to their wild-type littermates (Fig. 1b, c). The ef-
fect was reproduced in the MT5 tumor model (Fig. 1d).
The fact that loss of even one Dll1 allele produced sig-
nificantly accelerated disease indicates the importance of
DLL1 expression on DCs for tumor rejection.
In contrast, deletion of both alleles of Jag2 did not result
in major alteration in LLC tumor growth (Fig. 1e). There
was a tendency toward increased tumor volume, which
was not statistically significant. These results suggest that
abrogation of DLL1 but not Jag2 presentation by DC may
result in an altered anti-tumor immunity that could affect
tumor rejection.
Impaired anti-tumor T-cell IFN-γ production in tumor-
bearing mice lacking DLL1 in CD11c+ cells
To test whether genetic ablation of specific Notch ligands
in DCs affected cytokine secretion patterns, we evaluated
IFN-γ and IL-4 production in tumor-infiltrating T-cells by
ELISPOT assay following restimulation with CD3/CD28
antibody activator beads or with LLC tumor antigenic
MHC class-I-restricted peptide MUT1 loaded on autolo-
gous splenocytes. We found that in mice with hetero and
homozygous deletion of Dll1 in DCs, the numbers of
IFN-γ-producing MUT1-specific lymphocytes were mark-
edly decreased in the tumor, whereas the numbers of
tumor-infiltrating IL-4-producing cells were not altered
(Fig. 2a-c). Similarly, a reduction of IFN-γ-secreting lym-
phocytes was observed in the tumor-draining lymph nodes
(LN) (Fig. 2d). These observations provided the explan-
ation for the observed differences in tumor growth rates
by pointing to the crucial role of DC-expressed DLL1 for
the induction of anti-tumor cytotoxic T-cell responses.
In contrast to the striking effect of Dll1 deletion on
IFN-γ production, genetic ablation of Jag2 in DCs did
not have a major effect on the number of
tumor-infiltrating IFN-γ-producing cells. Abrogation of
Jag2-mediated signaling, however, resulted in the de-
creased generation of IL-4-secreting cells (Fig. 2e) con-
sistent with the reported role of Jag2 in Th2-type
differentiation.
Effects of CD11c+ cell lineage-specific deletion of Dll1 on
myeloid and lymphoid populations in tumor-bearing
mice
We performed extensive immunophenotyping of mye-
loid and lymphoid populations infiltrating the tumors
and in spleens of mice with CD11c+ lineage-specific het-
ero or homozygous deletion of Dll1 and their wild-type
littermates on day 17–18 after LLC tumor establishment.
The deletion of either one or two alleles of Dll1 resulted
in a moderate increase in total cell counts of
tissue-resident CD11b+CD11c+ DC populations in the
tumor or spleen compared to wild-type littermates, but
ability of DCs to undergo maturation or infiltrate the
tumor was not affected (Fig. 3a-c). Numbers of
CD11b+CD11c+ DCs expressing maturation markers
MHCII, CD40, CD80, CD86 and CD209 also did not
change (Fig. 3a, b, d). This is consistent with the hypoth-
esis that the observed alterations in anti-tumor T-cell re-
sponses is due to the absence of DLL1 expression on
DCs. Other obvious changes in the myeloid compart-
ment included increased numbers of CD11b+Gr-1+ cells
in Dll1-ablated mice. Further characterization showed
that both Ly6C+ monocytic and Ly6G+ granulocytic pop-
ulations of CD11b+Gr-1+ cells were significantly higher
in the tumors of DC-Dll1-ablated mice (Fig. 3a, d). In
the lymphoid organs of spleen and LN also, increased
numbers of CD11b+Gr-1+Ly6G+ granulocytic cells
were observed (Fig. 3b). On the other hand, a decline
was noted in the proportions of CD68+MHCII+F4/80+
M1 and CD68+MHCII+CD86+CD206+ M2 macro-
phages in the tumor-infiltrate and spleen of Dll1-ab-
lated mice (Fig. 3a, b).
Among lymphoid populations, a significantly increased
population of CD4+CD25+ T-cells was observed in
Dll1-ablated mice. Most of the tumor-infiltrating
CD4+CD25+ cells expressed FoxP3, and their proportion
was 2-fold higher in DC-specific Dll1−/− mice compared
to wild-type littermates (Fig. 4a, b). Deletion of Dll1 in
DCs also had a significant effect on CD8+ T-cells that
resulted in their decreased activation in the tumor as
shown by decreased expression of CD25 and CD44. The
proportions of intratumoral activated CD25+ and
central-memory CD44+CD62L+ CD8+T-cells were sig-
nificantly lower in knockout mice than in wild-type ani-
mals (Fig. 4a, b). These effects were, however, not
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prominent in splenocytes (Fig. 4c) suggesting that the
observed effects of Dll1 gene deletion may only be spe-
cific to the tumor microenvironment.
The above data show that abrogation of DLL1-me-
diated signaling favors Treg differentiation and accumu-
lation, and suppresses effector CD8+T-cells in the
tumor. These data indicate that genetic ablation of the
DC-expressed DLL1 affects T-cell differentiation and ac-
tivation programs to interfere with the generation of ef-
fective anti-tumor immune responses.
Pharmacological interference or enhancement of DLL1-
Notch signaling affects T-cell proliferation and effector
responses
Activation of Notch receptor proteolytic cleavage and
signaling requires a context-dependent multivalent inter-
action between Notch receptors and ligands, whereas
soluble monovalent forms of ligands are known to in-
hibit Notch signaling [24, 29]. We engineered a monova-
lent soluble DLL1 construct (sDLL1) comprising one
DSL and two N-terminal EGF repeat domains, and
A
B
D
C
E
Fig. 1 Genetic ablation of Dll1 in CD11c+ cells in mice accelerates tumor growth with decreased survival. a Deletion of Notch ligand genes Dll1
and Jag2 in CD11c+ cells was confirmed by RT-PCR performed with RNA isolated from CD11c+ or CD11c− cells from splenocytes of genetically
modified and wild-type mice. Lewis lung carcinoma (LLC) tumor growth (b) and log-rank survival curves (c) for mice with hetero or homozygous
deletion of Dll1 in CD11c+ cells and wild-type littermates. d Pancreatic MT5 tumor growth in CD11c+ cell-specific Dll1−/− and wild-type mice.
e LLC tumor growth in CD11c+ cell-specific Jag2−/− and wild-type littermates. Mean ± SEM, 8–10 mice per group; *, p < 0.05; **, p < 0.01
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compared its effects with multivalent clustered DLL1, a
complex formed by DLL1-IgG Fc fusion protein, bio-
tinylated anti-Fc antibodies and avidin that selectively
triggers DLL1-Notch signaling [24]. The monomeric
sDLL1 construct inhibited Notch signaling triggered by
multivalent clustered DLL1 as manifested by the
dose-dependent decrease in expression of the Notch
downstream target Hes1 mRNA in treated murine 3 T3
fibroblast cells (Fig. 5a). Thus, sDLL1 acts as a competi-
tive inhibitor of multivalent DLL1-triggered signaling.
To further confirm that DLL1-mediated Notch signal-
ing is required for efficient T lymphocyte function, we
assessed the effects of genetic versus pharmacological
interference with DLL1 signaling on the ability of DCs
to stimulate T-cell proliferation and function. DCs were
generated from wild-type or DC-specific Dll1−/− mouse
bone marrow cells, as described [30], and co-cultured
with allogeneic T-cells labeled with cell tracer fluores-
cent dye in the presence of soluble CD3 antibody. In
T-cell co-cultures with wild-type DCs, sDLL1 protein
was added to block DLL1-mediated signaling. DCs gen-
erated from Dll1−/− mouse showed impaired ability to
stimulate T-cell proliferation in contrast to wild-type
DCs. The presence of sDLL1 in T-cell stimulation
A B
C D
E
Fig. 2 CD11c-lineage-specific ablation of Notch ligands alters cytokine production. IFN-γ and IL-4-producing cells were enumerated by ELISPOT
assay among LLC tumor-infiltrating lymphocytes (TIL) from mice with CD11c lineage-specific deletion of Dll1 and wild-type littermates following
re-stimulation with anti-CD3/CD28 beads (a, b) or with LLC tumor antigenic peptide MUT1 (FEQNTAQP) loaded on autologous splenocytes for
48 h (c). d Evaluation of IFN-γ-producing cells in a pool of tumor-draining lymph node cells from the same mice following re-stimulation with
anti-CD3/CD28 beads. e Evaluation of IFN-γ and IL-4-producing cells among tumor-infiltrating lymphocytes from Jag2−/− or wild-type littermate
mice following re-stimulation with anti-CD3/CD28 beads. Mean ± SEM, 5 mice per group; *, p < 0.05, **, p < 0.01
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AB
C D
Fig. 3 CD11c-lineage-specific Dll1-ablated tumor-bearing mice exhibit no change in dendritic cells but increase CD11b+Gr1+ cell proportions.
Myeloid populations were evaluated by flow cytometry on day 17–18 after LLC tumor initiation in Dll1 knockout and wild-type littermate mice.
Percentage of indicated populations are shown in the tumor infiltrate (TIL) (a) and in a pool of splenocyte and LN cells (b). c Total cell yields in
the splenocytes and tumor single cell suspensions. d Representative FACS plots for CD11b versus CD11c, Ly6C or Ly6G staining (c). Mean ± SEM,
5–7 mice per group; *, p < 0.05; **, p < 0.01
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cultures also resulted in decreased T-cell proliferation as
assessed by the cell tracer dye dilution profile (Fig. 5b, c).
Moreover, LLC tumor-bearing wild-type mice treated with
sDLL1 significantly increased tumor growth (Fig. 5d),
similar to accelerated tumor growth seen in DC-specific
Dll1−/− mice (Fig. 1b). The inhibition with sDLL1 also re-
sulted in decreased IFN-γ-producing tumor-infiltrating
T-cells (Fig. 5e). Thus, pharmacological or genetic
A
B
C
Fig. 4 Tumor-bearing mice with CD11c-lineage-specific deletion of Dll1 exhibit increased Treg and decreased effector T-cell subsets. Lymphoid
populations were evaluated by flow cytometry on day 17–18 after LLC tumor initiation in Dll1 knockout and wild-type littermate mice.
Percentage of indicated populations are shown in CD4+ and CD8+ subsets in the tumor infiltrate (TIL) from knockout and wild-type littermates (a)
with representative flow plots for CD4 versus CD25, and CD8 versus CD25 (b) and in a pool of splenocytes and LN cell cells from the same mice
(c). Mean ± SEM, 5 mice per group, *, p < 0.05; **, p < 0.01
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disruption of DLL1-Notch interaction decreased T-cell
proliferation, IFN-γ production and anti-tumor T-cell
function, confirming the critical requirement for
DLL1-Notch signaling for DC-supported T-cell function.
We further tested the effect of interference with
DLL1-mediated Notch activation on the induction of
T-cell cytotoxic responses using the sDLL1 construct in
the non-tumor context of a cardiac allograft rejection.
C57BL/6 mice were transplanted with MHC-mis-
matched heterotopic BALB/c heart allografts and treated
with sDLL1 construct (1 mg/kg body weight, i.p.) or ve-
hicle control every 2 days. The sDLL1 treatment of
Fig. 5 Monomeric soluble DLL1 or Dll1-ablated dendritic cells restrict Notch signaling and impair T-cell cytotoxic responses. (a) Expression of
Notch downstream target Hes1 mRNA was assessed by qRT-PCR in 3 T3 cells treated with clustered DLL1 in the presence of soluble DLL1 (sDLL1)
construct at indicated concentrations for 16 h. b, c T-cell proliferation was measured after co-incubating allogeneic T-cells labeled with Cell Tracer
Violet fluorescent dye with bone marrow-derived Dll1−/− or wild-type DC in the presence of soluble anti-CD3 for 5 days. In some T-cell cultures
with wild-type DC, soluble DLL1 construct was added at the indicated concentrations. Representative Cell Tracer Violet dye dilution profile is
shown (b). d Tumor volume was measured in LLC tumor-bearing mice treated with sDLL1 construct 1 mg/kg body weight, i.p. every 2 days for
20 days. e IFN-γ producing tumor-infiltrating cells from these mice were enumerated by ELISPOT assay on day 18 after LLC tumor initiation. Mean
± SEM, 8 mice per group; *, p < 0.05; **, p < 0.005. f, g C57BL/6 mice were transplanted with BALB/c heart allografts on day 0 and treated with
sDLL1 construct (1 mg/kg) i.p. on days − 3, − 1, 1, 3, 5 and 7. f Heart allografted C57BL/6 mice log-rank survival. g IFN-γ ELISPOT assay on
recipient CD8+T cells isolated after heart allograft and re-stimulated with mitomycin C-treated donor spleen cells in the presence of recipient
C57BL/6 splenocytes. h Percentage of FoxP3+ cells among CD4+ splenocytes after heart allograft. Mean ± SEM, 4–8 mice per group; *, p < 0.05
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C57BL/6 recipient mice significantly prolonged host
allograft survival when compared to mice treated with
vehicle control (Fig. 5f ). This prolonged survival was as-
sociated with a decreased production of IFN-γ by
donor-reactive recipient C57BL/6 CD8+ T-cells follow-
ing restimulation with mitomycin-C-treated allogenic
donor BALB/c splenocytes in the presence of recipient
antigen-presenting cells (Fig. 5g). There was no major
shift toward IL-4 or IL-17 production (82 ± 7 vs. 84 ± 8
IL-4 spots and 16 ± 5 vs. 18 ± 2 IL-17 spots per 106
spleen cells for control and sDLL1-treated groups, re-
spectively), or in the proportion of CD4+FoxP3+ T-cells
(Fig. 5h). These data demonstrate that interference with
the DLL1-mediated Notch activation specifically sup-
presses induction of anti-tumor or alloreactive T-cell
responses.
In search for potential therapeutics to correct insuffi-
ciency or deficiency in DC-expressed DLL1-mediated
Notch activation pharmacologically, we tested the effi-
cacy of multivalent clustered DLL1 in the setting of
DLL1 deficiency in tumor-bearing hosts. The wild-type
or DC lineage-specific Dll1−/− mice were established
with lung LLC or pancreatic MT5 tumors and treated
with clustered DLL1 every two days for twenty days.
Clustered DLL1 treatments significantly reduced tumor
growth and prolonged survival in both wild-type and
DC-specific Dll1−/− animals (Fig. 6a, b).
These results with monomeric or clustered DLL1 con-
structs demonstrate that DLL1-based therapeutics has
the potential to attenuate or activate Notch signaling in
various disease conditions. Soluble DLL1 can prevent
allograft rejection, whereas clustered DLL1 can substi-
tute in large part for inadequate presentation of DLL1
by DCs needed for proper T-cell stimulation, and elicit
anti-tumor responses to reject tumors.
Monomeric soluble JAG1 construct decreases Treg
frequency, reduces PD-1 expression on CD8+Tem cells
and improves anti-tumor immunity
Our results showing differential cytokine patterns in
mice with DC-specific deletion of Dll1 and Jag2 ligands
suggested that Notch ligands had differential effects on
the induction of immune responses. We constructed a
monovalent soluble JAG1 (sJAG1) construct comprising
total five N-terminal domains (MNNL, DSL and 3 EGF
repeats) of mouse JAG1, and evaluated the significance
of JAG1-mediated Notch signaling in anti-tumor re-
sponses. LLC tumor-bearing mice were treated with
sJAG1 at a dose of 1 mg/kg body weight or vehicle con-
trol, i.p. every 2 days. The treatment with sJAG1 resulted
in significant reduction of tumor growth and improved
survival of animals (Fig. 6c, d). Moreover, these effects
were associated with the decreased numbers of
CD4+FoxP3+ Treg cells. We also noted significantly
reduced accumulation of tumor-infiltrating CD11b+Gr1+
cells (40.1 ± 8.3% vs. 11.0 ± 3.8% among CD45+ cells for
control and sJAG1-treated groups, respectively), and in-
creased IFN-γ production by lymphoid cells (Fig. 6f ).
These data suggest an important role of JAG1-mediated
Notch signaling in the induction of anti-tumor T-cell
responses.
We also assessed whether the engineered Notch ligand
DLL1 and JAG1 constructs modulate the differentiation
of memory T-cells in vitro in a T:DC stimulation
co-culture. Results show that inhibition with soluble
JAG1 or stimulation with clustered DLL1 constructs in-
creased the frequency of CD8+T-central memory cells
concomitant with a decrease in the frequency of
CD8+T-effector memory cells (Fig. 7a and
Additional file 1: Figure S1). The decrease in the fre-
quency of CD8+Tem cells was not due to exhaustion as
both constructs significantly decreased the expression of
checkpoint molecule PD-1 (about 3-fold by sJAG1 and
2.5-fold by clustered DLL1) in CD8+Tem cells, but not
in CD8+Tcm, in a dose-dependent manner (Fig. 7a and
Additional file 2: Figure S2). The expression of CTLA-4
was negligible and unchanged following treatments with
the constructs.
Dendritic cell-expressed NOTCH ligands correlate with
PD-1 or NOTCH receptor expression in CD8+ T-effector
memory population in human lung tumor-infiltrates
We sought to determine if there is a relationship between
the expression of NOTCH ligands on antigen presenting
cells and T-cell phenotype in human lung cancers. We
profiled the expression of NOTCH ligands, NOTCH re-
ceptors and PD-1 on various subsets of myeloid and
lymphoid cells in tumor-infiltrating immune cells in pri-
mary lung cancers. The analysis revealed a highly signifi-
cant correlation between the proportion of JAG1 or
JAG2-expressing tissue-resident CD11b+CD11chigh DCs
and the numbers of PD-1-expressing T-effector-memory
(Tem) CD8+CCR7−CD45RA− and T-terminal-effector
(Temra) CD8+CCR7−CD45RA+ cells, with JAG1 demon-
strating the strongest correlation (p = 0.0005) (Fig. 7b and
Additional file 3: Figure S3). Correlations between DC-
expressed DLL1 (p = 0.007) or DLL4 (p = 0.01) and PD-1
on Tem subsets were also observed; however, significance
of these correlations was substantially less than that for
JAG1 (Fig. 7b). Correlations between CD11b+CD11chigh
cells expressing JAG ligands and PD-1-expressing
CD8+CCR7+CD45RA− Tcm were marginal, with no sig-
nificant correlation between PD-1 in Tcm and Delta-like
ligands (Fig. 7b).
In contrast to PD-1, numbers of Tem cells expressing
NOTCH receptors highly significantly correlated with the
proportion of DCs expressing DLL1 or DLL4 (Fig. 7c).
While statistically significant correlation of
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Tem-expressed NOTCH2 and NOTCH3 was observed
with DC-expressed JAG1 and JAG2, it was less pro-
nounced. No statistically significant correlations were
identified for Tcm cells, except for NOTCH4 receptor
with DC-expressed JAG1, DLL1 and DLL4 (Fig. 7c). There
was no correlation between NOTCH ligand expression on
DCs and expression of PD-1 or NOTCH receptors in the
populations of CD8+CCR7+CD45RA+ naïve CD8 T cells
or naïve, effector or memory CD4 T-cells (Additional file
3: Figure S3). The above results imply that the interactions
between select DC-expressed Notch ligands and Notch re-
ceptors in T-cells present a key point of regulation for
A B
C D
E F
Fig. 6 Pharmacological manipulation of DLL1 or Jag1-mediated signaling reduces tumor growth and improves anti-tumor immunity. a, b
Enhancement of DLL1 signaling using multivalent clustered DLL1 overcomes the critical dendritic cell DLL1 deficiency and restricts tumor growth.
Growth of LLC tumor (a) and MT5 pancreatic tumor (b) in wild-type and DC-specific Dll1−/− mice. Mice were treated with 0.2 mg/kg body weight
of multivalent clustered DLL1-Fc fusion protein every 2 days for 20 days. Mean ± SEM, 8 mice per group; *, p < 0.05; **, p < 0.01. c, d Treatement
with soluble fragment of extracellular domain of JAG1 (sJAG1) significantly reduces tumor growth and improves survival of tumor-bearing mice.
LLC tumor growth (c) and log-rank survival curves (d) in mice treated with monovalent soluble JAG1 construct, 1 mg/kg body weight, i.p. every 2
days for 20 days. Percentage of FoxP3+ cells among CD4+ cells (e) and IFN-g ELISPOT (f) for splenocytes in mice treated with soluble JAG1 on day
18 after LLC tumor initiation. Mean ± SEM, 8–10 mice per group; *, p < 0.05; **, p < 0.01
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T-cell-mediated immunity by modulation of T-cell differ-
entiation and functionality in human lung tumors.
Discussion
Interaction of DCs with T lymphocytes is critical to deter-
mining the type and strength of the induced immune re-
sponse. Adequate presentation of antigens along with
other essential signals and cytokines provided by DCs are
necessary for the differentiation of effector T-cells and to
elicit a strong anti-tumor immunity. It is known that dis-
tinct inflammatory responses up-regulate expression of ei-
ther Delta-like or Jagged ligands in DCs to guide activated
CD4+ T-cells toward a specific type of T helper commit-
ment [12, 18]. The current study demonstrates that in
addition to the known T-cell differentiation signals, the
interaction between selective Notch ligands presented by
A C
B D
Fig. 7 Dendritic cell Jagged expression correlates with PD-1 expression on T-effector-memory cells. a Purified T cells were stimulated in vitro in a
T:DC (3:1) stimulation co-culture with allogeneic bone marrow-derived dendritic cells in the presence of CD3/CD28 beads (1 μg/mL) for four days
with or without treatment with clustered DLL1 (1.5 μg/mL) or monovalent soluble JAG1 (20 μg/mL) constructs. Expression of CD62L, CD44, CTLA-
4 and PD-1 was assessed on gated populations as indicated by flow cytometry. Dot plots from a representative experiment out of two
independent experiments with duplicates are shown. b-c Lung tumor single cell suspensions from 10 patients were evaluated for the expression
of NOTCH ligands on tissue-resident CD11b+CD11chigh dendritic cells and PD-1 and NOTCH receptors in populations of T cells by flow cytometry.
NOTCH ligands in CD11b+CD11chigh cells were compared to PD-1 positivity of Tem and Tcm cells (b) or to NOTCH receptor positive T cell
subsets by Pearson’s correlation (c.) All p-values were corrected using the Benjamani- Hochberg procedure; n = 8; * p < 0.05. Color code indicates
the strength of correlation. d Scheme summarizing available data on the regulation of T cell responses by Notch ligands
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DCs and Notch receptors on T-cells provide critical differ-
entiation signals, which function to polarize lymphocytes
towards T effector and memory cells. Our data show that
presentation of DLL1 by DCs is indispensable for the in-
duction of anti-tumor T-cell responses.
Notch signaling is highly responsive to variation in
Notch ligand expression in hematopoietic organs [31–33].
Previous studies showed that altered expression of Notch
ligands could underlie immunosuppression in cancer, and
in particular, expression of Delta-like ligands DLL1 and
DLL4 was significantly down-regulated in tumor-bearing
hosts [20, 24, 25]. DC lineage-specific genetic ablation or
systemic blockade of DLL1-Notch interaction, as shown
in this study, resulted in accelerated tumor growth in the
tested lung and pancreatic tumor models, likely due to in-
sufficient DLL1 signaling and consequent impairment of
anti-tumor immune responses. Deficiency in DLL1 ex-
pression in DCs resulted in a significant reduction of
CD8+ T-cell activation, tumor antigen-specific CTL and
differentiation of central memory CD8+CD44+CD62L+
T-cell populations. The DLL1 deficiency was also associ-
ated with an accumulation of monocytic and granulocytic
CD11b+Gr1+ cells and increased differentiation of Treg
cells. The results imply that the adequate expression of
DLL1 in DCs is a prerequisite for eliciting effector T-cells
and efficient anti-tumor responses.
Notch can orchestrate multiple T-cell lineage pro-
grams and concurrently regulate Th1, Th2 and Th17 cell
differentiation. In this function, Notch activity is thought
to be unbiased or unaffected by the cytokine environ-
ment [34]. Our study reveals that cell-lineage specific
ligand-receptor interactions determine the T-cell lineage
commitment and effector outcomes. Our findings in
mice with DC-specific ablation of Notch ligands and
therapeutic modulation in tumor and allograft rejection
settings by engineered ligand constructs support the
earlier gain-of-function observations [17, 18], and
strongly suggest the instructive nature of the interactions
between DC-expressed Notch ligands and T-cell Notch
receptors in regulating T lymphocyte commitment and
effector responses.
Notch1 and Notch2 have been identified as key Notch
receptors for eliciting T-cell effector function, including
anti-tumor responses. It was recently shown that Notch1
activation occurred in peripheral CD4+ T-cells in a
ligand-independent manner through chemical alterations
in the endosome within a few hours post–TCR stimula-
tion and was required for optimal T-cell activation [35].
Another study revealed the involvement of Notch signal-
ing in the regulation of T-cell metabolic reprogramming
and proposed that activation of Notch1 on Th cells by
DC-expressed DLL4 was essential for fine tuning the
sensitivity, magnitude and quality of the initial CD4+
T-cell responses upon antigen encounter [21]. Given the
confirmed functions of Notch1, Notch2 and DLL4 in
DC-T-cell interactions along with our data on the in-
volvement of DLL1 in Th cell polarization and CD8+
T-cell differentiation into effector and memory cells, it is
reasonable to hypothesize that the roles of different
Notch receptors and ligands are distinct during the mul-
tistep process of T-cell lineage commitment and differ-
entiation. The initial interaction between DC-expressed
DLL4 and T-cell Notch1 would support T-cell activation
and metabolic reprogramming, enhance expression of
Notch2 and potentially modulate the expression of other
Notch ligands. Engagement of Notch2 and DLL1 then
would drive effector T-cell differentiation and CTL re-
sponses. Altogether, the results point to a functional axis
of DLL4/DLL1 and Notch1/Notch2 as an essential elem-
ent in DC-T-cell interactions needed for the induction
of effector T-cell differentiation and eliciting
T-cell-mediated anti-tumor immunity.
Among Jagged family of Notch ligands, Jag2 was previ-
ously implicated in the induction of Th2 type responses
[16, 19, 33]. In our study, Jag2 deletion in DCs did not
result in any major changes in anti-tumor T-cell re-
sponses, such as IFN-γ production but had a negative ef-
fect on the number of IL-4 producing cells, consistent
with the role of Jag2 in supporting Th2 differentiation.
In contrast, pharmacological treatment with monomeric
soluble JAG1 resulted in remarkable inhibition of tumor
growth that was associated with the down-regulation of
Treg cell differentiation, significantly decreased tumor
infiltration with CD11c+Gr1+ cells, and enhanced IFN-γ
production. Together with recently published data im-
plicating Jag1 in regulating the suppressive function of
myeloid-derived suppressor cells (MDSC) [36], these
data identify Jag1 signaling as a prominent factor in im-
munosuppression mediated by both regulatory T-cells
and MDSC.
Analysis of human tumor-infiltrating immune cells
confirmed the potential link between expression of
Notch ligands by tissue-resident CD11b+CD11chigh DCs
and functional state of T-cells defined by their expres-
sion of PD-1 and Notch receptors. PD-1 expression is
regulated by multiple intercellular interactions, including
Notch-mediated transcriptional control of the Pdcd1
gene encoding PD-1 in CD8+ T cells [37]. Recently, stem
cell memory (scm)-like T-cells were generated from acti-
vated murine and human CD4+ and CD8+ T-cells by
coculturing with stromal cells presenting DLL1 ligand.
Further, Notch-mediated conversion of activated cells
into Tscm was associated with the loss of PD-1 and
CTLA-4 molecules [38]. We also show enhancement of
CD8+ Tcm populations with a decrease of PD-1 expres-
sion by clustered DLL1-triggered signaling or inhibition
of JAG1-mediated signaling. Our data have identified a
novel link between PD-1 expression in effector-memory
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T-cells and expression of Jagged ligands by DCs. This
Jagged-PD-1 axis is consistent with the inhibition of
anti-tumor T-cell activity and prevents the induction of
lasting T-cell-memory responses. Data also stress high
significance of Jag1 as a therapeutic target and indicate
that its blockade would be beneficial through multiple
mechanisms including decreased expression of PD-1 in
T-cells. Significance of the regulation of Notch receptors
in Tem cells by DC-expressed Notch ligands is yet to be
elucidated.
Available data on the roles of different Notch ligands
in regulation of T-cell differentiation are summarized in
Fig. 7c. With both Notch1 and 2 receptors involved,
higher DLL1 and DLL4 expression by DCs and other
antigen-presenting cells favors Th1 type and CD8+ CTL
responses [14, 24, 25]. Higher expression of Jag2 is
linked to predominant Th2 and likely Th17 type re-
sponses, whereas high expression of Jag1 and decreased
expression of Delta-like ligands supports regulatory
T-cell commitment [8, 15, 16, 19, 33, 39, 40].
The essential role of Notch ligands in the immune
regulation raises an important question about the fac-
tors that modulate their expression in DCs. A num-
ber of factors affecting expression of Notch ligands
have been identified in various cellular and tissue sys-
tems [41]. Some of them, including VEGF, FGF and
PGE2, have been implicated in the generation of dys-
functional or immunosuppressive DCs. It is conceiv-
able that part of these immunosuppressive effects
could be mediated via alteration of Notch ligand pres-
entation and shift from ligands critical for Th1 or
CTL differentiation toward ligands committed to
other T-cell lineages including Treg and Th2.
Identification of pharmacological approaches to modu-
late ligand-specific Notch signaling for the therapeutic
induction of immune responses could provide a power-
ful tool for directing polarization of T lymphocytes and
dissecting the T-cell differentiation requirements. We
tested approaches to modulate Th1 type, CTL and Treg
responses using multivalent activating or monovalent
inhibiting DLL1 and JAG1 constructs in lung and pan-
creatic tumor and cardiac allograft models. Therapeutic
activation of Notch signaling by clustered DLL1 in large
part restored deficient presentation of DLL1 by DCs.
Conversely, interference with ligand specific signaling
by monovalent soluble JAG1 or soluble DLL1 effi-
ciently improved anti-tumor immunity or blocked
anti-tumor and allogeneic T-cell responses, respect-
ively. The experiments with engineered mono- and
multivalent Notch ligands demonstrate the potential
of Notch ligand-based constructs in regulation of spe-
cific types of immune responses and open a venue for
exploration of a novel class of therapeutics for modu-
lating immunity.
Conclusions
We studied the effects of CD11c lineage-specific dele-
tion, inhibition or activation of Notch ligands on T-cell
function. Distinct immunoregulatory roles of Notch li-
gands were identified, with dendritic cell-expressed
DLL1 and JAG1 having opposing effect on CTL re-
sponses. Results suggest that engineered Notch ligand
constructs could be a novel class of immunomodulatory
drugs. However, no direct data are yet available to show
the efficacy of such Notch ligand constructs to human
cancers. Nevertheless, the consensus is building that
regulation of Notch in cancer immunity is a very attract-
ive approach [42] that will further enhance therapeutic
success in the ongoing revolution in cancer immuno-
therapy [43, 44]. Thus, strategies incorporating select-
ively engineered Notch ligands could open a new
approach of therapeutics for modulating immunity in
various immunosuppressive conditions including cancer.
Methods
Cell lines
Murine Lewis lung carcinoma (LLC) and 3 T3 cell lines
were obtained from the American Type Culture Collec-
tion (Manassas, VA). Murine MT5 pancreatic cells were
a kind gift from Dr. Tuveson (Cold Spring Harbor La-
boratory, Cold Spring Harbor, NY). Low-passage (less
than 10) cultures were used for the experiments. All ac-
tive cell cultures were checked for mycoplasma routinely
using a commercial PCR test. Purity and identity of cells
were also confirmed by flow cytometry (FACS) analysis
with antibodies to appropriate markers.
Mice and generation of DC lineage specific Notch ligand
knockout mice
Male and female C57BL/6 and BALB/c mice (7 to
8-week-old) used at equal numbers were purchased from
The Jackson Laboratory (Bar Harbor, MN).
C57BL/6 mice with floxed alleles for the Dll1 gene
were received from Dr. J. Lewis (Cancer Research UK,
London, UK); Jag2 gene-targeted floxed mice were
kindly provided by Dr. T. Gridley (Maine Medical Cen-
ter, Scarborough, MN). Generation of Dll1flox/flox and
Jag2flox/flox conditional knockout mice and genotyping of
floxed and deleted alleles have been described previously
[45–47]. B6.Cg-Tg(Itgax-cre)1-1Reiz/J mice expressing Cre
recombinase under the CD11c (integrin-αX; CD11c-Cre)
promoter were purchased from The Jackson Laboratory.
The animals were housed in pathogen-free units.
We generated mice bearing deletion of Dll1 or Jag2 in
CD11c+ cells by mating syngeneic B6.Cg-Tg(Itgax--
cre)1-1Reiz/J mice expressing Cre-recombinase under
CD11c promoter and DLL1flox/flox or Jag2flox/flox mice
and then by crossing their progeny. In the resultant
mice, CD11c+ cells with hetero- or homozygous allele
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deletion had genotype Dll1flox/−Cre+/−, Jag2flox/−Cre+/−,
Dll1−/−Cre+/− or Jag2−/−Cre+/−, respectively. Their litter-
mates with “floxed” alleles but without Cre recombinase
transgene served as respective controls in all animal ex-
periments. The allele deletion was confirmed by geno-
typing and by the assessment of Notch ligand mRNA
expression in flow-sorted CD11c+DC populations from
the spleen by PCR and RT-PCR using genomic DNA
and RNA samples, respectively, with sets of primers spe-
cific for floxed and deleted alleles and for ligand mRNA
described previously [24, 45–47] (Fig. 1a).
Expression levels of Notch ligands
RT-PCR was utilized to confirm deletion of Notch ligand
genes in CD11c+ cells. CD11c+ cells were isolated from
splenocytes by flow sorting, as described below. RNA was
extracted with RNeasy Mini kit and possible genomic
DNA contamination was removed by on-column DNase
digestion using the RNase-free DNase kit (Qiagen;
Valencia, CA). cDNA was synthesized using SuperScript
III Reverse Transcriptase kit (Invitrogen, Grand Island,
NY) and used in PCR reactions with gene-specific
primers, described previously [24]. Amplification of en-
dogenous β-actin was used as an internal control.
Pharmacological inhibition and activation of DLL1 and
JAG1 signaling
We engineered a DLL1 construct where part of the sol-
uble extracellular domain of mouse DLL1 protein com-
prising DSL, EGF1 and EGF2 domains with TEV and
6-His sequences was expressed in E. coli and isolated
using Ni-column (Bio-Rad, Hercules, CA). The prepar-
ation was 90% pure as assessed by polyacrylamide gel
electrophoresis with Coomassie R-250 staining. Mouse
JAG1 construct comprising MNNL, and DSL followed
by three EGF domains of JAG1 was produced in E. coli
by MyBiosource, Inc. (San Diego, CA). The inhibitory
activity of these reagents was confirmed by their ability
to decrease Hes1 expression in response to Notch stimu-
lation with the respective ligand in cell culture assay.
These constructs are referred to in the text and figures
as soluble DLL1 (sDLL1) and soluble JAG1 (sJAG1),
respectively.
Tumor model experiments and treatments
To induce tumors, mice were inoculated subcutaneously
(s.c.) in the flank with 0.25 × 106 LLC or 106 MT5 cells as
described previously [25, 30, 48]. Tumor volume was mea-
sured with calipers. For survival experiments, mice were
observed until they reached exclusion criteria as deter-
mined by the IACUC protocol. To evaluate immuno-
logical correlates, mice were euthanized on days 17–18
and 14–15 for LLC and MT5 models, respectively.
To inhibit ligand-specific Notch signaling, tumor-bear-
ing mice received sDLL1 or sJAG1 at a dose of 1 mg/kg
body weight (25 μg per injection) of the protein in 100 μl
of vehicle (Saline, 5% glycerol) intraperitoneally (i.p.)
every other day. The control groups received 100 μl of
saline vehicle instead of the ligand. Multivalent form of
DLL1 (clustered DLL1) was utilized to stimulate
DLL1-mediated Notch activation in vivo at a dose of 0.2
mg/kg body weight (5 μg per injection) of DLL1-Fc fu-
sion protein i.p. every other day, as described previously
[24, 25]. All treatments started at day 3–4 after tumor
injection.
Tumor cell suspension, lymphocyte enrichment and T-cell
functional analyses
Single cell suspensions of tumors from mice were pre-
pared using Miltenyi Biotec (Auburn, CA) Tissue dissoci-
ation kit and Gentle MACS instrument according to the
manufacturer’s recommendations. Lymphocytes were than
enriched by Lympholyte M (Cedarlane, Burlington,
Canada) gradient centrifugation and used to quantify the
cytokine producing cells. LLC cells express a defined anti-
genic peptide MUT1 (spontaneously mutated connexin
37), FEQNTAQP allowing evaluation of antigen-specific
CD8+T-cell responses [49]. Briefly, 5 × 105 cells per well
from the tumor cell suspensions or 2 × 105 cells per well
from tumor-draining LN were restimulated with 10 μM of
MUT1 or irrelevant control peptide loaded on autologous
mitomycin-C treated splenic cells for 48 h and IFN-γ or
IL-4-producing cells were evaluated by dual ELISPOT
assay (CTL, Shaker Heights, OH) according to the manu-
facturer’s protocol. Peptides were synthesized by the
American Peptide Company, Inc. (Sunnyvale, CA). Alter-
natively, gradient centrifugation-enriched cells (1.5 × 105
cells per well) were stimulated with Dynabeads Mouse
T-Activator CD3 and CD28 antibodies coupled to beads
(Life Technologies, Carlsbad, CA), as recommended by
the manufacturer, and IFN-γ or IL-4-producing cells were
enumerated by ELISPOT assay. Parts of tumor single cell
suspension, splenocytes and LN cell population from the
same mice were used for immunophenotyping of cells by
FACS (see below).
The effect of Notch ligand gene knockout on T-cell
stimulatory activity of DCs was evaluated in allogeneic
mixed lymphocyte reaction (MLR). DCs were generated
from bone marrow of wild type or knockout animals in
the presence of GM-CSF and IL-4, as described earlier
[30]. T-cells from allogeneic mice isolated by negative
selection using T-cell isolation columns (R&D Systems,
Minneapolis, MN) were labeled with Cell Tracer Violet
dye (ThermoFisher Sci., Grand Island, NY) and incu-
bated for 5 days with bone-marrow derived DC in the
presence of a soluble anti-CD3. Dye dilution in prolifer-
ating T-cells was measured by flow cytometry.
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Cardiac allograft rejection model
Wild type C57BL/6 mice were transplanted with
MHC-mismatched heterotopic BALB/c heart allografts
as previously described [50]. Mice with transplants were
treated with sDLL1 construct (1 mg/kg body weight, i.p.)
or vehicle control (Saline, 5% glycerol) on days − 3, − 1,
1, 3, 5 and 7 relative to the day of transplantation. Heart
allograft survival was evaluated daily by palpation, and
rejection was confirmed by laparotomy. IFN-γ ELISPOT
assay was performed on recipient splenic CD8+ T-cells
isolated at the time of graft rejection and restimulated
with mitomycin C treated donor BALB/c spleen cells in
the presence of self-antigen presenting cells.
Patient samples and analysis of PD-1 and NOTCH proteins
on tumor-infiltrating immune cells
Ten freshly resected de-identified lung cancer samples
were obtained under an informed consent from an unse-
lected patient population in terms of tumor types and
stages, age, sex and ethnicity. Tumor tissue single cell
suspensions were prepared using the Tissue dissociation
kit and Gentle MACS instrument from Miltenyi Biotec
according to the manufacturer’s recommendations. Cells
were live frozen until the analysis. Analysis of tumor- in-
filtrating immune cells was performed by flow cytometry
using lineage-specific antibodies and antibodies to PD-1,
NOTCH receptors and ligands. After gating for T-cell
and myeloid subsets, cell populations were further gated
by PD-1, Notch ligand, or Notch receptor positivity. Popu-
lations of PD-1-positive, Notch ligand-positive, or Notch
receptor-positive cells were compared using Pearson’s cor-
relation in R using the packages “Hmisc” and “corrplot”.
Flow cytometry and cell sorting
Fluorochrome-labeled cell surface or intracellular pro-
tein specific antibodies were obtained from BD Biosci-
ences, Pharmingen and eBioscience, Inc. (San Diego,
CA). For staining of cell-surface markers, cells were in-
cubated with the antibodies for 20 min on ice. For intra-
cellular FoxP3 staining, cells were first stained for
lineage-specific markers, then permeabilized for 20 min
with BD fixation/permeabilization kit and incubated
with fluorochrome-labeled FoxP3-specific antibody.
Matched fluorochrome-conjugated isotype IgG controls
were used as staining controls. Flow sorting of CD11c+
cells from splenocytes of wild type mice or animals with
Notch gene deletion was performed using Aria IIu cell
sorter (BD Immunocytometry). Nonviable cells were ex-
cluded using 7-amino actinomycin D staining. Antigen
negativity was defined as having the same fluorescent in-
tensity as the isotype control. FACS data were acquired
using a FACS LSR II (BD Immunocytometry) or a Guava
EasyCyte HT (Millipore) instrument and analyzed with
FlowJo software (Tree Star, Ashland, OR).
Statistical analysis
Data were analyzed using the GraphPad Prism 4.0 soft-
ware (GraphPad Software Inc., San Diego, CA) and pre-
sented as mean ± SEM. Comparisons between treatment
and control groups were performed using one-way
ANOVA followed by Dunnett’s post-tests. Comparisons
between two groups were performed using two-tailed
unpaired t tests. Survival curves were compared using
Mantel-Haenszel log rank test. The p-values for multiple
comparisons in human sample analyses were adjusted using
the Benjamani-Hochberg procedure. Differences were con-
sidered statistically significant when p-values < 0.05.
Additional files
Additional file 1: Figure S1. Clustered DLL1 and soluble JAG1
constructs modulate the differentiation of memory T-cells in vitro. Purified
T cells were stimulated in vitro in a T:DC (3:1) stimulation co-culture with
allogeneic bone marrow-derived dendritic cells in the presence of CD3/
CD28 beads (1 μg/mL) for four days with or without treatment with the in-
dicated concentrations of clustered DLL1 or monovalent soluble JAG1 con-
structs. Expression of CD62L and CD44 was assessed on gated CD8
population as indicated by flow cytometry. Dot plots from a representative
experiment out of two independent experiments with duplicates are
shown. (PPTX 4553 kb)
Additional file 2: Figure S2. Clustered DLL1 and soluble JAG1 constructs
decrease the expression of checkpoint molecule PD-1 on T-effector memory
cells in vitro. Purified T cells were stimulated in vitro in a T:DC (3:1) stimula-
tion co-culture with allogenic dendritic cells in the presence of CD3/CD28
beads (1 μg/mL) for four days with or without treatment with the indicated
concentrations of clustered DLL1 or monovalent soluble JAG1 constructs.
Expression of CTLA-4 and PD-1 was assessed on gated populations as indi-
cated by flow cytometry. Dot plots from a representative experiment out of
two independent experiments with duplicates are shown. (PPTX 8407 kb)
Additional file 3: Figure S3. T-cell expressed PD-1 and NOTCH receptors
correlate with DC-expressed NOTCH ligands in human lung tumor-infiltrate.
Heatmap shows Pearson’s correlation between the indicated populations.
P-values were corrected by Benjamani-Hochberg procedure. Color code
indicates the strength of correlation and direction; * p < 0.05. (PPTX 181 kb)
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Fig. 5 Monomeric soluble DLL1 or Dll1-ablated dendritic cells restrict Notch signaling and impair T-cell cytotoxic responses. a Expression of
Notch downstream target Hes1 mRNA was assessed by qRT-PCR in 3 T3 cells treated with clustered DLL1 in the presence of soluble DLL1 (sDLL1)
construct at indicated concentrations for 16 h. b, c T-cell proliferation was measured after co-incubating allogeneic T-cells labeled with Cell Tracer
Violet fluorescent dye with bone marrow-derived Dll1−/− or wild-type DC in the presence of soluble anti-CD3 for 5 days. In some T-cell cultures
with wild-type DC, soluble DLL1 construct was added at the indicated concentrations. Representative Cell Tracer Violet dye dilution profile is
shown (b). d Tumor volume was measured in LLC tumor-bearing mice treated with sDLL1 construct 1 mg/kg body weight, i.p. every 2 days for
20 days. e IFN-γ producing tumor-infiltrating cells from these mice were enumerated by ELISPOT assay on day 18 after LLC tumor initiation. Mean
± SEM, 8 mice per group; *, p < 0.05; **, p < 0.005. f, g C57BL/6 mice were transplanted with BALB/c heart allografts on day 0 and treated with
sDLL1 construct (1 mg/kg) i.p. on days − 3, − 1, 1, 3, 5 and 7. f Heart allografted C57BL/6 mice log-rank survival. g IFN-γ ELISPOT assay on
recipient CD8+T cells isolated after heart allograft and re-stimulated with mitomycin C-treated donor spleen cells in the presence of recipient
C57BL/6 splenocytes. h Percentage of FoxP3+ cells among CD4+ splenocytes after heart allograft. Mean ± SEM, 4–8 mice per group; *, p < 0.05
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Fig. 7 Dendritic cell Jagged expression correlates with PD-1 expression on T-effector-memory cells. a Purified T cells were stimulated in vitro in a
T:DC (3:1) stimulation co-culture with allogeneic bone marrow-derived dendritic cells in the presence of CD3/CD28 beads (1 μg/mL) for four days
with or without treatment with clustered DLL1 (1.5 μg/mL) or monovalent soluble JAG1 (20 μg/mL) constructs. Expression of CD62L, CD44, CTLA-
4 and PD-1 was assessed on gated populations as indicated by flow cytometry. Dot plots from a representative experiment out of two
independent experiments with duplicates are shown. b-c Lung tumor single cell suspensions from 10 patients were evaluated for the expression
of NOTCH ligands on tissue-resident CD11b+CD11chigh dendritic cells and PD-1 and NOTCH receptors in populations of T cells by flow cytometry.
NOTCH ligands in CD11b+CD11chigh cells were compared to PD-1 positivity of Tem and Tcm cells (b) or to NOTCH receptor positive T cell
subsets by Pearson’s correlation (c). All p-values were corrected using the Benjamani- Hochberg procedure; n = 8; * p < 0.05. Color code indicates
the strength of correlation. d Scheme summarizing available data on the regulation of T cell responses by Notch ligands
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